Elicera Therapeutics: Cell Therapy Company Under the Radar

Elicera Therapeutics: Cell Therapy Company Under the Radar - Carlsquare

Carlsquare Equity Research initiates coverage of Elicera Therapeutics and identifies a cancer research company with good potential. The Company is developing novel cell therapy therapies based on the enhancement of validated technologies. A primary focus is on the CAR-T area, where the market should multiply in the coming years. We estimate a risk-adjusted value of about SEK 13 per share. We see significant room for further appreciation upon clinical trials and business development progress.

The First Listed Swedish CAR-T-company Out of the Starting Blocks
Elicera is developing, among other things, new cancer treatments in CAR-T cell therapy, an area that has generated strong clinical results in patients with difficult-to-treat cancer and whose market should grow strongly in the coming years. Leading scientists back the Company, and Elicera’s candidates are differentiated with a proprietary technology to boost immune responses to cancer. So far, there is limited clinical data for Elicera’s portfolio, but the success of similar external projects bodes well. The corporate cash position is sufficient for the next two years. If outstanding warrants are exercised next year, financial sustainability will improve.

Benefitting from Regulatory and Financial support
Elicera intends to address rare cancers such as lymphoma and brain cancer, opening potentially faster clinical development than the average drug project. The projects have also received significant research funding. The aim is to license out projects and technology to essential partners, and examples of business development in the industry show that this can happen relatively early. At the same time, the risk of setbacks in clinical trials is high in drug development, as it is for Elicera’s project portfolio. However, we believe that the prospects for the Company’s immune-activating technology iTANK are not entirely dependent on a single project, which mitigates the technical risk to some extent

Weak Share Performance not Linked to Project Development
We believe that the low valuation, with a net asset value of over SEK 50 million, stands out compared to similar companies. An explanation is that Elicera already has one project in clinical development and is expected to add another in the coming year. The share price has been pressured by sell-offs related to a pre-IPO issue and, as expected, a somewhat limited news flow. We see the potential for more share price-driving news in 2022. We calculate a risk-adjusted justified value of SEK 13 in a base case scenario. In case of progress in clinical development, we estimate that the stock could double further in a bull scenario. The share is currently trading just above our bear scenario, where we only include the brain tumour project in our valuation.

Elicera Therapeutics: Cell Therapy Company Under the Radar - Carlsquare

Intervju med Mathias Svahn, Vd för NextCell Pharma

Magazine Börsvärlden Nr3 2025: Fokus på försvarsindustrin och oroliga marknader

Niklas Laninge på Opti om sparpsykologi, risk och varför vi borde leva mer – inte bara spara

Bra Snack – Avsnitt 28 april 2025

Type1water revolutionerar vattenrening – investera i nästa generations teknik

ORINK – Svensk havrekraft på global frammarsch

Publicera din analys på Börsvärlden

Aktuellt just nu!

Intervju med Mathias Svahn, Vd för NextCell Pharma

Magazine Börsvärlden Nr3 2025: Fokus på försvarsindustrin och oroliga marknader

Niklas Laninge på Opti om sparpsykologi, risk och varför vi borde leva mer – inte bara spara

Bra Snack – Avsnitt 28 april 2025

Type1water revolutionerar vattenrening – investera i nästa generations teknik

ORINK – Svensk havrekraft på global frammarsch

Publicera din analys på Börsvärlden

Aktuellt just nu!

Elicera Therapeutics: Cell Therapy Company Under the Radar - Carlsquare

Intervju med Mathias Svahn, Vd för NextCell Pharma

Magazine Börsvärlden Nr3 2025: Fokus på försvarsindustrin och oroliga marknader

Niklas Laninge på Opti om sparpsykologi, risk och varför vi borde leva mer – inte bara spara

Bra Snack – Avsnitt 28 april 2025

Type1water revolutionerar vattenrening – investera i nästa generations teknik

ORINK – Svensk havrekraft på global frammarsch

Publicera din analys på Börsvärlden

Aktuellt just nu!

Intervju med Mathias Svahn, Vd för NextCell Pharma

Magazine Börsvärlden Nr3 2025: Fokus på försvarsindustrin och oroliga marknader

Niklas Laninge på Opti om sparpsykologi, risk och varför vi borde leva mer – inte bara spara

Bra Snack – Avsnitt 28 april 2025

Type1water revolutionerar vattenrening – investera i nästa generations teknik

ORINK – Svensk havrekraft på global frammarsch

Publicera din analys på Börsvärlden

Aktuellt just nu!

Antalet aktiva olje- och gasriggar i Kanada backade 6,3 procent till 120 stycken senaste veckan

Antalet aktiva olje- och gasriggar i USA sjönk 0,5 procent till 584 stycken senaste veckan

JP Morgans globala inköpschefsindex för tillverkningssektorn minskade i april

Inköpschefsindex för industrin i Mexiko sjönk i april

Japan kan använda innehav av statsobligationer som ett förhandlingskort med USA

Samtycke till nyhetsbrev